Breast cancer is the most common and most preventable cancer in women and early detection has the important role in reducing its morbidity and mortality, so increase 95% survival time. The present study conducted to compare the effects of two educational methods on knowledge, attitude and practices of Arak physicians. An interventional study after randomized allocation of each 64 physician to any of two different educational methods (video and systematic review) used to compare knowledge; attitude and practices score variation about breast cancer screening skills. Data collection carried out with structured questionnaire and entered to SPSS software. Data analyzed by t-test, paired t-test and Man-Whitney test in significant level of 0.05. Mean of total score of knowledge, attitude and practices (KAP) showed a significant difference before and after training and the total score of KAP increase (p < 0.05). But KAP score variation and their subscales were same in two groups and didn't show any significant difference (p > 0.05). Although KAP in Arak physician is appropriate and any educational program increase their KAP level, but continuing and repetition of educational courses seems to be necessary.
The Iranian-made Imatinib can be used as a replacement for Indian made ones without any statistical and clinical significant difference on Improvement of CML patients.
Background:Currently, imatinib is the drug of choice for initiation of medical treatment of chronic myeloid leukemia (CML) in the chronic phase. The current study was carried out to compare effectiveness and safety of Iranian vs. Indian imatinib.Materials and Methods:The clinical study was performed on newly diagnosed CML patients in Seyyed-oShohada Hospital (Isfahan) and Khansari Hospital (Arak) from January to June 2011. The control group consisted of CML patients who received Indian imatinib previously. The drug was initiated with the dose of 400 mg daily. The patients were followed for six months, and the treatment outcomes (WBC <104) and molecular response. Finally, the two groups were compared in these respects.Result:We evaluated 43 patients in each group. The hematological and molecular responses for the Iranian Imatinib were respectively 86.0% and 46.5%, while the rates were respectively 86.0 and 44.2% for the Indian imatinib. The two groups were similar with regard to the treatment outcome. The two groups were not significantly different with regard to the drug adverse effects.Conclusion:According to the findings, the Iranian imatinib is not different from the Indian drug in the hematological and molecular responses in treatment of the chronic phase of CML patients. Furthermore, the adverse effects of the two kinds were not significantly different. Compared with the results of other studies, the effectiveness of Iranian imatinib is equivalent to the Indian drug can be employed for treatment of CML patients in the chronic phase.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.